Tellgen (SHE:300642) obtained regulatory approval for the expanded use of its human papillomavirus nucleic acid detection and 16/18 genotyping kit, according to a filing with the Shenzhen bourse.
China's National Medical Products Administration approved the kit's use for primary cervical cancer screening, co-testing with cervical cytology for screening, and triaging patients with ambiguous ASC-US cytology results.
Shares of the detection products company closed 2% lower Wednesday.